Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Haematology Other
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Haematology Other
    FDA Approves Eltrombopag for the Treatment of Chronic Immune Thrombocytopenic Purpura - (DGNews)
    Percutaneous Patent Foramen Ovale Closure Safe for Patients With Thrombophilia: Presented at AHA - (DGDispatch)
    Home Coagulation Testing Appears Safe for Patients Receiving Warfarin Therapy: Presented at AHA - (DGDispatch)
    Heparin Dose Should Not Be Adjusted By Weight: Presented at CCC - (DGDispatch)
    FDA Approves Drug to Prevent Joint Damage in Children with Haemophilia A - (DGNews)

    News archive

     Recent webcasts/CME - Haematology Other
  • Clinical Implications of New Data on Iron Overload in Patients With MDS
  • Practical Implications of New Canadian Guidelines on Treating Iron Overload in MDS
  • Heparin-Induced Thrombocytopenia: Diagnosis and Treatment

    Webcasts/CME archive

     Recent cases - Haematology Other
      Multiorgan Failure Due to Hemophagocytic Syndrome: A Case Report
      Pancytopenia and Atrial Fibrillation Associated with Chronic Hepatitis C Infection and Presumed Hepatocellular Carcinoma: A Case Report
      Caterpillar-Induced Bleeding Syndrome in a Returning Traveller
      Colchicine Related Pancytopenia Unresponsive to Granulocyte Colony Stimulating Factor
      Life-Threatening Biopsy of an Iliopsoas Pseudotumour in a Patient with Haemophilia: A Case Report

      Cases archive
        




      my personal edition > haematology other > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Antithrombin Concentrate May Effectively Treat Severe Preeclampsia

      A DGReview of :"Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study"
      Seminars in Thrombosis and Hemostasis

      01/30/2004
      By Jill Taylor


      Antithrombin (AT) concentrate as treatment for preeclampsia improved clinical signs, corrected hypercoagulability, and improved foetal status, according to a Japanese study.

      Preeclampsia is a pregnancy-specific syndrome of unknown aetiology associated with vasospasms, pathological vascular lesions, and activation of the coagulation system. The main clinical findings are elevated blood pressure combined with proteinuria, which can lead to foetal and maternal complications.

      The level of AT, the major inhibitor that forms irreversible complexes with various clotting factors, appears to be correlated with maternal and foetal morbidity in preeclampsia. Furthermore, evidence suggests that in preeclampsia, acquired AT deficiency is secondary to a hypercoagulable state and/or associated with impaired hepatic and/or renal function.

      Takao Kobayashi, MD, PhD, of the Shinshu University of Health Sciences, Matsumoto City, Nagano Prefecture, Japan, and colleagues performed prospective feasibility study designed to determine whether AT therapy benefits clinical signs and foetal well being in cases of severe preeclampsia.

      A total of 29 preeclamptic patients, at 24 to 36 weeks of gestation, were randomised to receive either intravenous AT concentrate 1500 U/day for 7 days with heparin 5000 U/day (AT group), or heparin 5000 U/day only (control group). No statistically significant differences existed in the clinical profiles between the two groups.

      Study endpoints included gestosis index (GI) improvement, biophysical profile score (BPS) improvement, pregnancy duration, birth weight, gestational age at delivery, coagulation abnormality improvement, and neonatal death due to preeclampsia or stillbirth.

      Response to treatment was assessed based on the difference between pre- and post-treatment values. Results showed that compared with the control group, the AT group showed a significantly better response in both GI (P = .046) and BPS (P = .022). Additionally, the AT antigen levels and AT activity both increased significantly (P < .001, each), but showed no significant changes in the control group.

      While no significant changes occurred between groups for individual coagulation parameters, the coagulation index decreased significantly (P = .008) in the AT group, with no significant change in the control group.

      Few drug-related adverse events occurred in either group, and no significant difference was found between the AT group and control group.

      Additionally, significant differences were not observed between the 2 groups in pregnancy and neonatal outcome. One neonatal death, which was attributed to extreme prematurity resulting from severe preeclampsia, occurred in the control group.

      "These results support the hypothesis that the pathogenesis of preeclampsia involves hypercoagulability, especially thrombin-induced endothelial cell dysfunction," the researchers concluded.

      Semin Thromb Hemost 2003 Dec;29:6:645-52. "Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send